#Novo

The U.S. Food and Drug Administration will now require GLP-1 drugs to carry warnings about a serious potential side effect.

Novo posted quarterly earnings ahead of expectations early Wednesday as sales of its Wegovy pill blew past estimates

Novo released new evidence that its experimental CagriSema injection can improve upon the weight loss with its blockbuster GLP-1 obesity injection, Wegovy.

CVS will add Zepbound coverage on Oct. 1, and start covering Lilly's newly approved Foundayo pill on June 1.

Novo Nordisk released new data that could help boost the case for the higher dose version of its blockbuster obesity injection Wegovy.

Cellular Intelligence just acquired the rights to an experimental Parkinson’s cell therapy from Novo Nordisk.

Novo Nordisk A/S saw a 40% surge in sales of its diabetes and weight-loss drugs in India last month, after steep price cuts boosted demand for its branded treatments even as generic GLP-1 therapies flood the market.

New generics in Canada likely mark the start of a decline in international revenue of semaglutide, the active ingredient in Novo's Ozempic and Wegovy.

From Google News - World: Novo Nordisk CEO says the drugmaker is more active than ever in seeking out deals - CNBC

Novo Nordisk A/S (NOVO:CA) Q1 2026 Earnings Call May 6, 2026 7:00 AM EDTCompany ParticipantsMichael Novod - Senior VP & Head of Investor RelationsMaziar...

Novo Nordisk CEO Mike Doustdar says the Ozempic and Wegovy maker is looking for deals more than ever before.

From Independent RSS Feed: Novo Nordisk shares soar as sales of Wegovy weight loss pill smash forecasts

From Independent RSS Feed: Wegovy maker Novo Nordisk boosted by successful weight loss pill launch

Novo Nordisk raised its outlook for 2026 after a strong performance from its newly launched Wegovy pill.

Early signs from the launch of Novo Nordisk's Wegovy pill and Eli Lilly & Co.'s Foundayo are making investors rethink the opportunity for GLP-1 pills.

Early signs from the launch of Novo Nordisk's Wegovy pill and Eli Lilly & Co.'s Foundayo are making investors rethink the opportunity for GLP-1 pills.

If that proposal is finalized, the exclusion would likely limit the mass compounding of those medicines ​unless they appear on the FDA's ⁠drug shortage ⁠list.

It'll probably take several years before generic semaglutide could arrive stateside.